Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Postinfectious bronchiolitis obliterans in children: lessons from bronchiolitis obliterans after lung transplantation and hematopoietic stem cell transplantation

  • Yu, Jinho (Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine)
  • 투고 : 2015.02.20
  • 심사 : 2015.06.13
  • 발행 : 2015.12.10
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Postinfectious bronchiolitis obliterans (PIBO) is an irreversible obstructive lung disease characterized by subepithelial inflammation and fibrotic narrowing of the bronchioles after lower respiratory tract infection during childhood, especially early childhood. Although diagnosis of PIBO should be confirmed by histopathology, it is generally based on history and clinical findings. Irreversible airway obstruction is demonstrated by decreased forced expiratory volume in 1 second with an absent bronchodilator response, and by mosaic perfusion, air trapping, and/or bronchiectasis on computed tomography images. However, lung function tests using spirometry are not feasible in young children, and most cases of PIBO develop during early childhood. Further studies focused on obtaining serial measurements of lung function in infants and toddlers with a risk of bronchiolitis obliterans (BO) after lower respiratory tract infection are therefore needed. Although an optimal treatment for PIBO has not been established, corticosteroids have been used to target the inflammatory component. Other treatment modalities for BO after lung transplantation or hematopoietic stem cell transplantation have been studied in clinical trials, and the results can be extrapolated for the treatment of PIBO. Lung transplantation remains the final option for children with PIBO who have progressed to end-stage lung disease.

키워드

참고문헌

  1. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. N Engl J Med 2014;370:1820-8. https://doi.org/10.1056/NEJMra1204664
  2. Spigelblatt L, Rosenfeld R. Hyperlucent lung: long-term complication of adenovirus type 7 pneumonia. Can Med Assoc J 1983; 128:47-9.
  3. Becroft DM. Bronchiolitis obliterans, bronchiectasis, and other sequelae of adenovirus type 21 infection in young children. J Clin Pathol 1971;24:72-82. https://doi.org/10.1136/jcp.24.1.72
  4. Herbert FA, Wilkinson D, Burchak E, Morgante O. Adenovirus type 3 pneumonia causing lung damage in childhood. Can Med Assoc J 1977;116:274-6.
  5. Kim CK, Kim SW, Kim JS, Koh YY, Cohen AH, Deterding RR, et al. Bronchiolitis obliterans in the 1990s in Korea and the United States. Chest 2001;120:1101-6. https://doi.org/10.1378/chest.120.4.1101
  6. Koh YY, Jung da E, Koh JY, Kim JY, Yoo Y, Kim CK. Bronchoalveolar cellularity and interleukin-8 levels in measles bronchiolitis obliterans. Chest 2007;131:1454-60. https://doi.org/10.1378/chest.06-0188
  7. Laraya-Cuasay LR, DeForest A, Huff D, Lischner H, Huang NN. Chronic pulmonary complications of early influenza virus infection in children. Am Rev Respir Dis 1977;116:617-25. https://doi.org/10.1164/arrd.1977.116.4.617
  8. Hardy KA, Schidlow DV, Zaeri N. Obliterative bronchiolitis in children. Chest 1988;93:460-6. https://doi.org/10.1378/chest.93.3.460
  9. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ. Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 2003;9:657-66. https://doi.org/10.1016/S1083-8791(03)00242-8
  10. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW. Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 1988;72:621-7.
  11. Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, et al. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest 2005;128:153-61. https://doi.org/10.1378/chest.128.1.153
  12. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17:1072-8. https://doi.org/10.1016/j.bbmt.2010.11.018
  13. Zhang L, Irion K, Kozakewich H, Reid L, Camargo JJ, da Silva Porto N, et al. Clinical course of postinfectious bronchiolitis obliterans. Pediatr Pulmonol 2000;29:341-50. https://doi.org/10.1002/(SICI)1099-0496(200005)29:5<341::AID-PPUL2>3.0.CO;2-4
  14. Yalcin E, Dogru D, Haliloglu M, Ozcelik U, Kiper N, Gocmen A. Postinfectious bronchiolitis obliterans in children: clinical and radiological profile and prognostic factors. Respiration 2003;70: 371-5. https://doi.org/10.1159/000072900
  15. Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW. Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives? Bone Marrow Transplant 2013;48:1224-9. https://doi.org/10.1038/bmt.2013.17
  16. Nakaseko C, Ozawa S, Sakaida E, Sakai M, Kanda Y, Oshima K, et al. Incidence, risk factors and outcomes of bronchiolitis obliterans after allogeneic stem cell transplantation. Int J Hematol 2011;93: 375-82. https://doi.org/10.1007/s12185-011-0809-8
  17. Benden C, Goldfarb SB, Edwards LB, Kucheryavaya AY, Christie JD, Dipchand AI, et al. The registry of the International Society for Heart and Lung Transplantation: seventeenth official pediatric lung and heart-lung transplantation report--2014; focus theme: retransplantation. J Heart Lung Transplant 2014;33:1025-33. https://doi.org/10.1016/j.healun.2014.08.005
  18. Mauad T, Dolhnikoff M; Sao Paulo Bronchiolitis Obliterans Study Group. Histology of childhood bronchiolitis obliterans. Pediatr Pulmonol 2002;33:466-74. https://doi.org/10.1002/ppul.10097
  19. Kennedy VE, Todd JL, Palmer SM. Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome. Am J Transplant 2013;13:552-61. https://doi.org/10.1111/ajt.12091
  20. Devouassoux G, Drouet C, Pin I, Brambilla C, Brambilla E, Colle PE, et al. Alveolar neutrophilia is a predictor for the bronchiolitis obliterans syndrome, and increases with degree of severity. Transpl Immunol 2002;10:303-10. https://doi.org/10.1016/S0966-3274(02)00074-6
  21. Hubner RH, Meffert S, Mundt U, Bottcher H, Freitag S, El Mokhtari NE, et al. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2005;25:494-501. https://doi.org/10.1183/09031936.05.00091804
  22. Riise GC, Ericson P, Bozinovski S, Yoshihara S, Anderson GP, Linden A. Increased net gelatinase but not serine protease activity in bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010;29:800-7. https://doi.org/10.1016/j.healun.2010.02.010
  23. Behr J, Maier K, Braun B, Schwaiblmair M, Vogelmeier C. Evidence for oxidative stress in bronchiolitis obliterans syndrome after lung and heart-lung transplantation. The Munich Lung Transplant Group. Transplantation 2000;69:1856-60. https://doi.org/10.1097/00007890-200005150-00020
  24. Hirsch J, Elssner A, Mazur G, Maier KL, Bittmann I, Behr J, et al. Bronchiolitis obliterans syndrome after (heart-)lung transplantation. Impaired antiprotease defense and increased oxidant activity. Am J Respir Crit Care Med 1999;160(5 Pt 1):1640-6. https://doi.org/10.1164/ajrccm.160.5.9902012
  25. Riise GC, Williams A, Kjellstrom C, Schersten H, Andersson BA, Kelly FJ. Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J 1998;12:82-8. https://doi.org/10.1183/09031936.98.12010082
  26. Nelsestuen GL, Martinez MB, Hertz MI, Savik K, Wendt CH. Proteomic identification of human neutrophil alpha-defensins in chronic lung allograft rejection. Proteomics 2005;5:1705-13. https://doi.org/10.1002/pmic.200401036
  27. Ditschkowski M, Elmaagacli AH, Trenschel R, Peceny R, Koldehoff M, Schulte C, et al. T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors. Haematologica 2007;92:558-61. https://doi.org/10.3324/haematol.10710
  28. Burlingham WJ, Love RB, Jankowska-Gan E, Haynes LD, Xu Q, Bobadilla JL, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest 2007;117:3498-506. https://doi.org/10.1172/JCI28031
  29. Nakagiri T, Inoue M, Morii E, Minami M, Sawabata N, Utsumi T, et al. Local IL-17 production and a decrease in peripheral blood regulatory T cells in an animal model of bronchiolitis obliterans. Transplantation 2010;89:1312-9. https://doi.org/10.1097/TP.0b013e3181d8ea16
  30. Cazzato S, Poletti V, Bernardi F, Loroni L, Bertelli L, Colonna S, et al. Airway inflammation and lung function decline in childhood post-infectious bronchiolitis obliterans. Pediatr Pulmonol 2008; 43:381-90. https://doi.org/10.1002/ppul.20784
  31. Mosquera RA, Hashmi SS, Pacheco SE, Reverdin A, Chevallier J, Colasurdo GN. Dysanaptic growth of lung and airway in children with post-infectious bronchiolitis obliterans. Clin Respir J 2014;8: 63-71. https://doi.org/10.1111/crj.12037
  32. Colom AJ, Teper AM. Clinical prediction rule to diagnose post-infectious bronchiolitis obliterans in children. Pediatr Pulmonol 2009;44:1065-9. https://doi.org/10.1002/ppul.21080
  33. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002;21:297-310. https://doi.org/10.1016/S1053-2498(02)00398-4
  34. Hutchison AA, Erben A, McLennan LA, Landau LI, Phelan PD. Intrasubject variability of pulmonary function testing in healthy children. Thorax 1981;36:370-7. https://doi.org/10.1136/thx.36.5.370
  35. Chien JW, Duncan S, Williams KM, Pavletic SZ. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010;16(1 Suppl):S106-14. https://doi.org/10.1016/j.bbmt.2009.11.002
  36. Fisher AJ, Gabbay E, Small T, Doig S, Dark JH, Corris PA. Cross sectional study of exhaled nitric oxide levels following lung transplantation. Thorax 1998;53:454-8. https://doi.org/10.1136/thx.53.6.454
  37. Neurohr C, Huppmann P, Leuschner S, von Wulffen W, Meis T, Leuchte H, et al. Usefulness of exhaled nitric oxide to guide risk stratification for bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant 2011;11:129-37. https://doi.org/10.1111/j.1600-6143.2010.03327.x
  38. Fischer GB, Sarria EE, Mattiello R, Mocelin HT, Castro-Rodriguez JA. Post infectious bronchiolitis obliterans in children. Paediatr Respir Rev 2010;11:233-9. https://doi.org/10.1016/j.prrv.2010.07.005
  39. Ratjen F, Rjabko O, Kremens B. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children. Bone Marrow Transplant 2005;36:135-8. https://doi.org/10.1038/sj.bmt.1705026
  40. Glanville AR, Baldwin JC, Burke CM, Theodore J, Robin ED. Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. Ann Intern Med 1987;107:300-4. https://doi.org/10.7326/0003-4819-107-2-300
  41. Dusmet M, Maurer J, Winton T, Kesten S. Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant 1996;15:948-54.
  42. Browne PV, Weisdorf DJ, DeFor T, Miller WJ, Davies SM, Filipovich A, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant 2000;26:865-9. https://doi.org/10.1038/sj.bmt.1702626
  43. Stadler M, Ahlborn R, Kamal H, Diedrich H, Buchholz S, Eder M, et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009;114:3718-9. https://doi.org/10.1182/blood-2009-07-231159
  44. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82:45-52. https://doi.org/10.1002/ajh.20752
  45. Aguerre V, Castanos C, Pena HG, Grenoville M, Murtagh P. Postinfectious bronchiolitis obliterans in children: clinical and pulmonary function findings. Pediatr Pulmonol 2010;45:1180-5. https://doi.org/10.1002/ppul.21304
  46. Teixeira MF, Rodrigues JC, Leone C, Adde FV. Acute bronchodilator responsiveness to tiotropium in postinfectious bronchiolitis obliterans in children. Chest 2013;144:974-80. https://doi.org/10.1378/chest.12-2280
  47. Lam DC, Lam B, Wong MK, Lu C, Au WY, Tse EW, et al. Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study. Bone Marrow Transplant 2011;46:1551-6. https://doi.org/10.1038/bmt.2011.1
  48. Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med 2003; 168:121-5. https://doi.org/10.1164/rccm.200212-1424BC
  49. Yates B, Murphy DM, Forrest IA, Ward C, Rutherford RM, Fisher AJ, et al. Azithromycin reverses airflow obstruction in established bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2005; 172:772-5. https://doi.org/10.1164/rccm.200411-1537OC
  50. Khalid M, Al Saghir A, Saleemi S, Al Dammas S, Zeitouni M, Al Mobeireek A, et al. Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study. Eur Respir J 2005;25:490-3. https://doi.org/10.1183/09031936.05.00020804
  51. Rama JA, Fan LL, Faro A, Elidemir O, Morales DL, Heinle JS, et al. Lung transplantation for childhood diffuse lung disease. Pediatr Pulmonol 2013;48:490-6. https://doi.org/10.1002/ppul.22634

피인용 문헌

  1. Montelukast, current indications and prospective future applications vol.10, pp.9, 2015, https://doi.org/10.1080/17476348.2016.1207533
  2. Clinical features of postinfectious bronchiolitis obliterans in children undergoing long-term nebulization treatment vol.14, pp.5, 2015, https://doi.org/10.1007/s12519-018-0193-z
  3. Six‐minute walk, lung clearance index, and QOL in bronchiolitis obliterans and cystic fibrosis vol.54, pp.4, 2019, https://doi.org/10.1002/ppul.24223
  4. Diagnosing and managing bronchiolitis obliterans in children vol.13, pp.5, 2015, https://doi.org/10.1080/17476348.2019.1586537
  5. Calprotectin as a New Sensitive Marker of Neutrophilic Inflammation in Patients with Bronchiolitis Obliterans vol.2020, pp.None, 2015, https://doi.org/10.1155/2020/4641585
  6. Lung Transplant Pathology vol.13, pp.1, 2015, https://doi.org/10.1016/j.path.2019.11.003
  7. Cryobiopsy in the diagnosis of bronchiolitis: a retrospective analysis of twenty-three consecutive patients vol.10, pp.None, 2015, https://doi.org/10.1038/s41598-020-67938-y
  8. A follow-up study of post infectious obliterative bronchiolitis in adults and comparative analysis with chronic obstructive pulmonary disease vol.38, pp.6, 2015, https://doi.org/10.4103/lungindia.lungindia_95_21
  9. Clinical features and pulmonary function in children with Swyer-James-Macleod syndrome: A single center experience vol.9, pp.3, 2021, https://doi.org/10.4168/aard.2021.9.3.156
  10. Longitudinal Assessment of Pulmonary Function and Bronchodilator Response in Pediatric Patients With Post-infectious Bronchiolitis Obliterans vol.9, pp.None, 2021, https://doi.org/10.3389/fped.2021.674310
  11. Fibrotischer Lungenparenchymumbau nach Lungen- und Stammzelltransplantation vol.42, pp.1, 2015, https://doi.org/10.1007/s00292-020-00898-2
  12. Long‐term course of bronchial inflammation and pulmonary function testing in children with postinfectious bronchiolitis obliterans vol.56, pp.9, 2015, https://doi.org/10.1002/ppul.25547